

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61L 31/00	A1	(11) International Publication Number: WO 99/62572 (43) International Publication Date: 9 December 1999 (09.12.99)
(21) International Application Number: PCT/EP99/03022 (22) International Filing Date: 27 April 1999 (27.04.99) (30) Priority Data: 98201835.0 3 June 1998 (03.06.98) EP (71) Applicant (for all designated States except US): N.V. BEKAERT S.A. [BE/BE]; Bekaertstraat 2, B-8550 Zwevegem (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): DE SCHEERDER, Ivan [BE/BE]; Eikeldreef 9, B-9830 Sint-Martens-Latem (BE). DEMEYERE, Eddy [BE/BE]; Edward Vermeulenstraat 11, B-8510 Marke (BE). NEERINCK, Dominique [BE/BE]; Verbindingsstraat 21, B-8020 Hertsberge (BE). COPPENS, Wilfried [BE/BE]; Cyriel Verschaevestraat 7, B-8510 Marke (BE). (74) Agents: MESSELY, Marc et al.; N.V. Bekaert S.A., Bekaertstraat 2, B-8550 Zwevegem (BE).		(81) Designated States: IN, JP, SG, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: STENTS WITH A DIAMOND LIKE COATING		
(57) Abstract An intravascular metal stent having a tubular wall and a biocompatible coating on at least a major part of the wall surface which coating has a thickness of less than 4 μ m and contains a diamond like amorphous material, preferably DLN.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

WO 99/62572

PCT/EP99/03022

STENTS WITH A DIAMOND LIKE COATING**Field of the invention.**

5 The present invention relates to an intravascular stent which is coated with a specific biocompatible composition.

Background of the invention.

10 It is known that heparin, phosphorylcholine and certain polymer coatings may decrease the thrombogenicity of coronary stents. However they do not appear to reduce neointimal hyperplasia and in-stent restenosis. A large variety of vasoactive substances can easily be embedded in the polymer network without firm chemical bonds. Consequently they potentially can act as an intramural slow release formulation for vasoactive drugs.

15 Numerous tubular stent designs are now on the market. Many of them consist of a radially expandable metal network, either in the form of a fine wire mesh, of a corrugated ring structure or of a slotted metal tube wall wherein a recurring pattern of holes are cut (e.g. by laser cutting). The stent wall has a thickness of between 0.08 and 0.20 mm and the metal is preferably stainless steel, tantalum or NITINOL. Stents can also have an expandable tubular metal spring like structure (coil stent). Examples of stent structures are known from e.g. US patents Nos. 4,739,762, 4,856,516, 5,133,732, 5,135,536, 5,161,547, 5,158,548, 5,183,085, 20 5,282,823, from WO 94/17754, from European patent applications Nos. 0282175, 0382014, 0540290, 0621017, 0615769, 0669114, 0662307, 25 0657147 and from European patent application 0791341 of applicant.

30 Diamond like amorphous material such as diamond like nano composition (DLN) are known from WO97/40207 and WO98/33948.

The use of DLN as biocompatible coating for medical devices is for example known from US 5,352,493, WO 97/40207 and WO 96/39943. US 5,352,493 and WO96/39943 disclose the application of DLN as 35 biocompatible coating for medical devices such as orthopedic devices.

WO 99/62572

PCT/EP99/03022

-2-

WO 97/40207 describes the application of DLN for coating of hip prostheses.

In contrast with the above mentioned applications, the coating of intravascular implants, such as stents must meet more severe requirements. The coating needs not only to meet the requirement to be biocompatible, but has to decrease or even to avoid thrombogenicity and histiolympocytic inflammatory foreign body reaction. Neointimal hyperplasia has to be avoided since it can result in a narrowing or even in a closing of the blood vessel cavity. The narrowing of the blood vessel cavity after implantation of a stent is known as in-stent restenosis.

Summary of the invention.

It is an object of the present invention to provide an intravascular stent coated with a biocompatible material in order to avoid thrombogenicity, histiolympocytic inflammatory foreign body reaction and neointimal hyperplasia. As a consequence the risk for in-stent restenosis is decreased or avoided.

The object of the invention is met by using a new class of biocompatible materials for coating at least a major part of the wall surface of the stent with a coating thickness of preferably less than 4 μm and most preferably between 0.05 and 3 μm . The material used according to the invention contains a diamond like amorphous material. Since the coating resists repeated deformation, it can be applied to a stent with a radially expandable metal mesh or metal coil structure.

The diamond like amorphous material in the coating is preferably a diamond like nano composition (DLN) comprising interpenetrating networks of a-C:H and a-Si:O. Such coatings and methods to apply them are known i.a. from WO 97/40207, PCT/EP97/01878 and WO98/33948. A representative coating of a-C:H and a-Si:O comprises 30 to 70 at% of C, 20 to 40 at% of H, 5 to 15 at% of Si and 5 to 15 % of O. For applying these

WO 99/62572

PCT/EP99/03022

-3-

coatings to stents, the latter are preferably in their expanded state, not only radially but also they are longitudinally (axially) stretched to a certain extent if the mesh or spring structure so permits. This allows a substantially uniform deposition of the biocompatible diamond like material (DLN) using plasma-assisted CVD-processes. The plasma is created from a siloxane precursor. A Si-doped DLC can also be deposited; a silane precursor is then used.

Description of the preferred embodiments of the invention.

The invention will now be illustrated by the description of two exemplary embodiments. The coronary stent of a coil-type design was used, as described in US patent 5,183,085. It consisted of a preconditioned, non ferromagnetic, highly polished stainless steel wire (AISI 316L) with a diameter of 0.18 mm. This design allows folding (radial compression) on any conventional balloon, resulting in a low profile 6F guiding catheter compatible stent delivery system. Percentage of axial shortening upon expanding the balloon is less than 5 % and the stent is available in lengths from 12 mm up to 40 mm allowing customized stenting. These stents are available as bare stents or as mounted stents. In the present example stents of a length of 16 mm were used. Highly polished laser cut stainless steel mesh stents can be used as well.

The coil stent in its radially expanded form (as shown figure 1 of US patent 5,183,085) was mounted as cathode in the vacuum reactor where the diamond like nanocomposition was deposited.

In a first embodiment, a single diamond like nanocomposition material (DLN) of the type described in claim 2 of WO 97/40207 was deposited with an average thickness of 2.5 μm . In a second embodiment a coating with the same thickness was deposited, using essential features of the process of WO 98/33948. This means that a first layer of the diamond like nanocomposite material was deposited with an average thickness of 0.5

WO 99/62572

PCT/EP99/03022

-4-

5 μm . On top of that a layer of the same average thickness of diamond like carbon (DLC= a-C:H) was deposited with a transition layer interbetween having a thickness of 1.5 μm and comprising a mixture with a composition changing gradually from the first nanocomposition (DLN) to the DLC. The coating on the outer side of the coil was generally slightly thicker than on its inner side. The outer surface of the coated wire of the stent was extremely even and smooth.

10 Both embodiments were subjected to cyclic fatigue bending tests to determine their adhesion behaviour and adhesion retention to the wire after a number of bending cycles. No significant separation of the coating from the steel surface was discovered, especially for the stent with the single DLN-coating since indeed the critical load in a scratch test had indicated before a value of 33 to 36 N. The scratch tests were performed at
15 about 50 % relative humidity at 22 °C with a Revetest device (CSEM). The scratch stylus used is a diamond Rockwell C tip (120°C on with a 200 μm tip radius). The loading rate is 100 N/mm, whereas the displacement rate of the stylus on the coating is 10 mm per minute. The critical load is determined with optical microscopy and corresponds to the load where
20 delamination of the coating starts at the edges of the scratch track. It is thus confirmed here that DLN offers an excellent adhesion and adhesion retention after repeated bending. The inert diamond like material presents at the same time a suitable protective layer against possible corrosive attack of the steel surface (release of Cr, Ni and/or Fe) by the blood and
25 vascular tissue in contact with the stent surface.

30 The stents were then radially compressed on a balloon catheter (diameter 3 to 3.5 mm) to the configuration shown in figure 3 of US patent 5,183,085 and randomly implanted in a series of coronary arteries of 20 domestic cross bred pigs of both sexes weighing 25 to 30 kg. Thirteen specimen of each of three types of stents, viz. coated stents according to the first and to the second embodiment described above and (as third type) non coated,

WO 99/62572

PCT/EP99/03022

-5-

highly polished stainless steel spring stents were implanted for comparison. All stent deployments and implantations were successful and resulted in properly stented vessel segments. The pigs were fed throughout the study period with a standard natural grain diet without lipid or cholesterol supplementation. All animals were treated and cared for in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. Six weeks after implantation, control angiography of the stented vessels was performed and subsequently pigs were sacrificed. At that time their average weight was about 70 kg and the vessels had thus grown considerably, compared to their size at the time of implantation.

Angiographic analysis (quantitative coronary angiography) of stented vessel segments was performed before stenting, immediately after stenting, and at follow-up using the POLYTRON 1000-system as described by De Scheerder et al. in the Journal of Invasive Cardiology 1996; 8: 215-222. The lumen diameters of the vessel segments were measured before stent implantation (= pre-stenting artery diameter values), immediately thereafter (= post-stenting values) and at follow-up (= diameters after 6 weeks). The degree of oversizing (%) was expressed as measured maximum balloon size minus selected artery diameter divided by the selected artery diameter. Recoil (%) was expressed as measured maximum balloon size minus minimal stent lumen diameter (measured 15 minutes after stent implantation) and divided by measured maximum balloon size. The late loss value is an indication of hyperplasia and is the difference between the post-stenting value and the diameter at follow-up. The results of the angiographic measurements for each of the three types of stents is summarized in table 1.

WO 99/62572

PCT/EP99/03022

-6-

TABLE 1

Mean Artery diameter (mm)	Non-coated	Coating DLN	Coating DLN/DLC
Pre-stenting (mm)	2.52 ± 0.18	2.57 ± 0.22	2.41 ± 0.18
Balloon size (mm)	2.93 ± 0.16	2.96 ± 0.10	2.91 ± 0.15
Post-stenting (mm)	2.68 ± 0.16	2.71 ± 0.20	2.64 ± 0.14
Oversizing (%)	16 ± 6	16 ± 8	21 ± 7
Recoil (%)	8 ± 4	8 ± 4	9 ± 6
6 weeks FU (mm)	2.52 ± 0.29	2.65 ± 0.27	2.54 ± 0.37
Late loss	0.16 ± 0.28	0.06 ± 0.27	0.10 ± 0.34

Baseline selected arteries, measured balloon diameter and post stenting diameter were similar for the three types. Oversizing and recoil were also similar. At six week follow-up a somewhat larger minimal luminal stent diameter and a somewhat decreased late loss was found for the DLN-coated stent embodiment.

After the pigs were sacrificed coronary segments were carefully dissected together with 10 mm minimum vessel segment both proximal and distal to the stent. Histopathology, as evaluated by light microscopic examination, was performed on very thin cross-section slices of the stented artery sections. Injury of the arterial wall, due to stent deployment, was evaluated as a first factor and graded according to the method of Schwartz et al. (J.Am. Coll. Cardiol 1992; 19: 267-274). Likewise, inflammatory reaction at every stent filament site was examined (second factor) by searching for inflammatory cells and graded as well. Appearance of thrombus was evaluated as a third factor and graded. The mean value of every factor for the 12 samples of each of the three stent types was calculated.

Thrombus formation was decreased in both coated stent types, i.e. with coatings DLN, resp. DLN/DLC. However, histopathology revealed for the

WO 99/62572

PCT/EP99/03022

-7-

non-coated stents and for the DLN/DLC-coated stents an increased inflammatory reaction when compared to the stent type with the single DLN-coating. It is believed that the inert DLN-coating is particularly useful to retard the attraction and sticking of proteins to the stent surface.

5

Finally, a morphometric study was carried out on the stented vessel segments at the time of follow-up after six weeks of implantation. The study was made using a computerized morphometry program (Leitz CBA 8000). Measurements of lumen area, lumen inside the internal elastic lamina area (=IEL area) and lumen inside the external elastic lamina area (=EEL area) were performed on the arterial sites, all in mm². Neointimal hyperplasia (= IEL area minus Lumen area) and area stenosis in % as the ratio of hyperplasia to IEL area were derived therefrom. The results are shown in table 2.

15

TABLE 2

Mean Cross Section Area (mm ²)	Non-coated	Coating DLN	Coating DLN/DLC
Lumen area (mm ²)	1.71 ± 0.66	2.31 ± 0.89	1.93 ± 0.73
IEL area (mm ²)	3.87 ± 1.39	3.84 ± 0.67	3.59 ± 0.54
EEL area (mm ²)	5.74 ± 2.06	5.15 ± 0.89	4.95 ± 0.66
Hyperplasia (mm ²)	2.16 ± 1.48	1.53 ± 0.54	1.66 ± 0.38
Area stenosis (%)	54 ± 15	41 ± 17	48 ± 16

20

Again the DLN-coated stents offered the best results, i.e. the largest lumen area after 6 weeks, caused by a decreased neointimal hyperplasia.

Covering the DLN/DLC- or DLN-coated stents with a heparin or phosphorycholine layer may further decrease neointimal hyperplasia.

WO 99/62572**PCT/EP99/03022****-8-**

Although the invention has been described for blood vessels, similar results can be obtained for stents with diamond like coatings in other vessels in animal and human bodies, such as life stream conducts.

WO 99/62572

PCT/EP99/03022

-9-

CLAIMS

1. An intravascular stent having a tubular wall and a biocompatible coating on at least a major part of the wall surface, said coating having
5 a thickness of less than 4 μm and containing a diamond like nanocomposite (DLN) material, said nanocomposite material comprising two interpenetrating networks of a-C:H and a-Si:O.
2. A stent according to claim 1 wherein the stent wall is a radially
10 expandable metal mesh or metal spring structure.
3. A stent according to claim 1 wherein the material comprises 30 to 70 at% of C, 20 to 40 at% of H, 5 to 15 at% of Si and 5 to 15 % of O.
- 15 4. A stent according to claim 1 wherein the material closest to the wire surface is a nanocomposite DLN-material comprising interpenetrating networks of a-C:H and a-Si:O and wherein this material is covered with a transition layer comprising a mixture of said nanocomposite DLN and
20 a diamond like carbon (DLC) layer and further with a DLC-layer.
5. A stent according to claim 2 wherein the metal structure is a polished stainless steel structure.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/03022

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61L31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 352 493 A (PYPKIN BORIS ET AL) 4 October 1994 (1994-10-04) cited in the application claims; example 4 ---	1-5
X	WO 97 40207 A (BEKAERT SA NV ;NEERINCK DOMINIQUE (BE); GOEL ARVIND (US)) 30 October 1997 (1997-10-30) cited in the application page 11, line 18 - line 25; claims ---	1-5
X	GB 2 287 473 A (FRANKS DR JOSEPH) 20 September 1995 (1995-09-20) claims ---	1-5
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

31 August 1999

Date of mailing of the international search report

08/09/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

ESPINOSA, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/03022

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 39943 A (ADVANCED REFRACTORY TECH) 19 December 1996 (1996-12-19) cited in the application page 20, line 34 - line 37; claims ---	1-5
P,X	WO 98 33948 A (N.V. BEKAERT S.A.) 6 August 1998 (1998-08-06) cited in the application claims ---	1
A	US 5 647 858 A (DAVIDSON JAMES A) 15 July 1997 (1997-07-15) claims ---	1
A	US 5 163 958 A (PINCHUK LEONARD) 17 November 1992 (1992-11-17) claims; figure 2 ---	1
A	CHANDRA L ET AL: "THE EFFECT OF BIOLOGICAL FLUIDS ON THE ADHESION OF DIAMOND-LIKE CARBON FILMS TO METALLIC SUBSTRATES" DIAMOND AND RELATED MATERIALS, vol. 4, no. 5/06, 1 May 1995 (1995-05-01), pages 852-856, XP000512522 ---	
A	OLBORSKA A ET AL: "AMORPHOUS CARBON - BIOMATERIAL FOR IMPLANT COATINGS" DIAMOND AND RELATED MATERIALS, vol. 3, no. 4/06, 1 April 1994 (1994-04-01), pages 899-901, XP000466689 ---	
A	MITURA E ET AL: "DIAMOND-LIKE CARBON COATINGS FOR BIOMEDICAL APPLICATIONS" DIAMOND AND RELATED MATERIALS, vol. 3, no. 4/06, 1 April 1994 (1994-04-01), pages 896-898, XP000466688 ---	
A	GB 2 128 637 A (TECHNION RES & DEV FOUNDATION) 2 May 1984 (1984-05-02) -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr. 1st Application No

PCT/EP 99/03022

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5352493 A	04-10-1994	US 5466431 A	14-11-1995
		US 5728465 A	17-03-1998
		US 5718976 A	17-02-1998
		US 5786068 A	28-07-1998
WO 9740207 A	30-10-1997	AU 2697797 A	12-11-1997
		EP 0896640 A	17-02-1999
GB 2287473 A	20-09-1995	NONE	
WO 9639943 A	19-12-1996	US 5728465 A	17-03-1998
		AU 5980596 A	30-12-1996
WO 9833948 A	06-08-1998	EP 0856592 A	05-08-1998
US 5647858 A	15-07-1997	US 5496359 A	05-03-1996
		US 5282850 A	01-02-1994
		US 5258022 A	02-11-1993
		US 5152794 A	06-10-1992
		US 5037438 A	06-08-1991
		US 5549667 A	27-08-1996
		US 5588443 A	31-12-1996
		US 5632779 A	27-05-1997
		US 5611347 A	18-03-1997
		US 5649951 A	22-07-1997
		US 5628790 A	13-05-1997
		AU 675450 B	06-02-1997
		AU 4786293 A	14-02-1994
		CA 2141183 A	03-02-1994
		EP 0746266 A	11-12-1996
		JP 8501953 T	05-03-1996
		WO 9402083 A	03-02-1996
		AU 660893 B	06-07-1995
		AU 3217593 A	05-08-1993
		CA 2088696 A	05-08-1993
		EP 0555038 A	11-08-1993
		JP 5269192 A	19-10-1994
		AU 639468 B	29-07-1993
		AU 5980790 A	31-01-1991
		DE 69005219 D	27-01-1994
		DK 410711 T	11-04-1994
		EP 0410711 A	30-01-1991
		ES 2048435 T	16-03-1994
		JP 4144555 A	19-05-1993
		CA 2021814 A	26-01-1991
		US 5370694 A	06-12-1992
		US 5180394 A	19-01-1993
US 5163958 A	17-11-1992	NONE	
GB 2128637 A	02-05-1984	US 4486286 A	04-12-1984
		DE 3335132 A	03-05-1984